Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jul 24, 2026
Artiva Biotherapeutics, Inc. (ARTV)
A forensic read on Artiva Biotherapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Grey Zone
Financial health
4.7
Altman Z-score
Clean
Earnings quality
1
Forensic signals
-76.3%
ROE
$250M
Market cap
Artiva Biotherapeutics, Inc. earns a F (Poor — capital at risk) forensic quality grade, and its Altman Z-score is 4.7, placing it in the Grey zone. 1 forensic signal was flagged in its latest SEC filings, led by share count (stock split).
What the filings flag
n/m (stock split)
FY2024–FY2025
Share count (stock split).Diluted share count changed +117% over the last 1 years to FY2025, but that includes a large one-time change around FY2025 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw +117.1%/yr figure isn't a real buyback/dilution read here.
Key fundamentals
Free Cash Flow$-80.2M
Return on Equity-76.3%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Artiva Biotherapeutics, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about ARTV's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown